DNA methylation levels of RELN promoter region in ultra-high risk, first episode and chronic schizophrenia cohorts of schizophrenia
Open Access
- 10 October 2022
- journal article
- research article
- Published by Springer Nature in Schizophrenia
- Vol. 8 (1) , 1-9
Abstract
The essential role of the Reelin gene (RELN) during brain development makes it a prominent candidate in human epigenetic studies of Schizophrenia. Previous literature has reported differing levels of DNA methylation (DNAm) in patients with psychosis. Therefore, this study aimed to (1) examine and compare RELN DNAm levels in subjects at different stages of psychosis cross-sectionally, (2) analyse the effect of antipsychotics (AP) on DNAm, and (3) evaluate the effectiveness and applicability of RELN promoter DNAm as a possible biological-based marker for symptom severity in psychosis.. The study cohort consisted of 56 healthy controls, 87 ultra-high risk (UHR) individuals, 26 first-episode (FE) psychosis individuals and 30 chronic schizophrenia (CS) individuals. The Positive and Negative Syndrome Scale (PANSS) was used to assess Schizophrenia severity. After pyrosequencing selected CpG sites of peripheral blood, the Average mean DNAm levels were compared amongst the 4 subgroups. Our results showed differing levels of DNAm, with UHR having the lowest (7.72 ± 0.19) while the CS had the highest levels (HC: 8.78 ± 0.35; FE: 7.75 ± 0.37; CS: 8.82 ± 0.48). Significantly higher Average mean DNAm levels were found in CS subjects on AP (9.12 ± 0.61) compared to UHR without medication (UHR(−)) (7.39 ± 0.18). A significant association was also observed between the Average mean DNAm of FE and PANSS Negative symptom factor (R2 = 0.237, ß = −0.401, *p = 0.033). In conclusion, our findings suggested different levels of DNAm for subjects at different stages of psychosis. Those subjects that took AP have different DNAm levels. There were significant associations between FE DNAm and Negative PANSS scores. With more future experiments and on larger cohorts, there may be potential use of DNAm of the RELN gene as one of the genes for the biological-based marker for symptom severity in psychosis.Keywords
Funding Information
- MOH | National Medical Research Council (NMRC/CNIG/1150/2016)
This publication has 46 references indexed in Scilit:
- Continuous Aging of the Human DNA Methylome Throughout the Human LifespanPLOS ONE, 2013
- Functional annotation of the human brain methylome identifies tissue-specific epigenetic variation across brain and bloodGenome Biology, 2012
- Is the PANSS used correctly? a systematic reviewBMC Psychiatry, 2011
- The Genetic Variation of RELN Expression in Schizophrenia and Bipolar DisorderPLOS ONE, 2011
- Neocortical RELN promoter methylation increases significantly after pubertyNeuroReport, 2010
- Chronic psychotropic drug treatment causes differential expression of Reelin signaling system in frontal cortex of ratsSchizophrenia Research, 2009
- Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylationProceedings of the National Academy of Sciences, 2008
- The human reelin gene: Transcription factors (+), repressors (−) and the methylation switch (+/−) in schizophreniaPharmacology & Therapeutics, 2006
- Mapping the Onset of Psychosis: The Comprehensive Assessment of At-Risk Mental StatesAustralian & New Zealand Journal of Psychiatry, 2005
- Early detection strategies for untreated first-episode psychosisSchizophrenia Research, 2001